Regulatory posture
Sermorelin was previously FDA approved as Geref for diagnostic and pediatric growth hormone deficiency use, but that product was withdrawn from the US market and is no longer commercially available. As of 2026 there is no FDA approved sermorelin product, and it is sometimes prepared through compounding, an area of ongoing regulatory attention regarding peptide compounding standards. It is not a controlled substance under the DEA.
Mechanism, plain English
Sermorelin is a shortened synthetic version of growth hormone releasing hormone, the natural signal that tells the pituitary gland to make and release growth hormone. By acting on the same receptor as the natural hormone, it prompts the body to produce its own growth hormone in a more natural, pulsed way. Its historical medical use was mainly to test how well the pituitary gland works and to treat growth hormone deficiency in children.
Evidence landscape
The peer-reviewed evidence for sermorelin is older and centered on its diagnostic role and pediatric growth hormone deficiency rather than modern anti-aging or wellness claims. A review of its use describes its role in diagnosing and treating idiopathic growth hormone deficiency in children, reflecting its original approved purpose. A later editorial review discussed sermorelin as a physiologic approach to adult-onset growth hormone insufficiency, but framed this as a concept rather than a robustly proven therapy. Foundational reviews of growth hormone releasing hormone explain the biology underlying sermorelin and related analogs. Contemporary efficacy and safety data in healthy adults are limited.
Primary PubMed citations
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency , Prakash A et al, BioDrugs, 1999. PMID: 18031173
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? , Walker RF et al, Clinical Interventions in Aging, 2006. PMID: 18046908
- Growth hormone releasing hormone , Grossman A et al, Clinics in Endocrinology and Metabolism, 1986. PMID: 2429796
Citations selected from the PubMed literature. Every URL was checked at publication time. Scriptura's daily PubMed scan surfaces new studies for each compound as they index. See the regulatory and literature layers on the demo.
This is a plain English summary of the peer reviewed literature and current regulatory posture. It is not a substitute for a licensed clinician's judgment on a specific patient. It does not recommend dosing, cadence, or route. Where the literature is limited or preclinical, this page says so, so a prescriber can weigh marketing claims against what the trials actually show.